UroGen Pharma (NASDAQ:URGN – Free Report) had its price target cut by Oppenheimer from $34.00 to $32.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have an outperform rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $54.00 target price on shares of UroGen Pharma […]
UroGen Pharma s (URGN) Buy Rating Reiterated at HC Wainwright themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
UroGen Pharma (NASDAQ:URGN – Get Free Report) will issue its quarterly earnings data before the market opens on Thursday, March 14th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link. UroGen Pharma Trading Down […]
Clal Insurance Enterprises Holdings Ltd lessened its stake in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 58.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 222,159 shares of the company’s stock after selling 307,229 shares during the quarter. Clal Insurance Enterprises Holdings […]
Stonepine Capital Management LLC decreased its position in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 36.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 448,508 shares of the company’s stock after selling 253,027 shares during the period. UroGen Pharma makes […]